These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

780 related items for PubMed ID: 30676706

  • 1. [Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors].
    Verburg AFE, van den Donk M, Wiersma T.
    Ned Tijdschr Geneeskd; 2019 Jan 14; 163():. PubMed ID: 30676706
    [Abstract] [Full Text] [Related]

  • 2. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D, Christiansen MN, Mogensen UM, Bundgaard JS, Rørth R, Madelaire C, Fosbøl EL, Schou M, Torp-Pedersen C, Gislason G, Køber L, Kristensen SL.
    Cardiovasc Diabetol; 2020 Jul 06; 19(1):107. PubMed ID: 32631337
    [Abstract] [Full Text] [Related]

  • 3. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V, Elharram M, Moura CS, Abrahamowicz M, Bernatsky S, Behlouli H, Pilote L.
    J Am Heart Assoc; 2020 Jan 07; 9(1):e012940. PubMed ID: 31902326
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and DPP-4 Inhibitors as an Add-On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review.
    Chai S, Niu Y, Liu F, Wu S, Yang Z, Sun F.
    J Diabetes Res; 2024 Jan 07; 2024():8145388. PubMed ID: 39072050
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes.
    O'Brien MJ, Karam SL, Wallia A, Kang RH, Cooper AJ, Lancki N, Moran MR, Liss DT, Prospect TA, Ackermann RT.
    JAMA Netw Open; 2018 Dec 07; 1(8):e186125. PubMed ID: 30646315
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
    Alfayez OM, Al Yami MS, Alshibani M, Fallatah SB, Al Khushaym NM, Alsheikh R, Alkhatib N.
    Prim Care Diabetes; 2019 Jun 07; 13(3):204-211. PubMed ID: 30713085
    [Abstract] [Full Text] [Related]

  • 12. SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study.
    Fu EL, Wexler DJ, Cromer SJ, Bykov K, Paik JM, Patorno E.
    BMJ; 2024 Jun 26; 385():e078483. PubMed ID: 38925801
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, Tunnicliffe D, Ruospo M, Natale P, Saglimbene V, Nicolucci A, Johnson DW, Tonelli M, Rossi MC, Badve SV, Cho Y, Nadeau-Fredette AC, Burke M, Faruque LI, Lloyd A, Ahmad N, Liu Y, Tiv S, Millard T, Gagliardi L, Kolanu N, Barmanray RD, McMorrow R, Raygoza Cortez AK, White H, Chen X, Zhou X, Liu J, Rodríguez AF, González-Colmenero AD, Wang Y, Li L, Sutanto S, Solis RC, Díaz González-Colmenero F, Rodriguez-Gutierrez R, Walsh M, Guyatt G, Strippoli GFM.
    BMJ; 2021 Jan 13; 372():m4573. PubMed ID: 33441402
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX, Liang S, Gao L, Liu H.
    PLoS One; 2021 Jan 13; 16(2):e0244689. PubMed ID: 33606705
    [Abstract] [Full Text] [Related]

  • 17. Treatment trajectories for Danish individuals with type 2 diabetes in the era of emerging glucose-lowering therapies.
    Pottegård A, Andersen JH, Søndergaard J, Rasmussen L, Kildegaard H, Vilsbøll T, Thomsen RW.
    Diabetes Obes Metab; 2024 Nov 13; 26(11):4996-5004. PubMed ID: 39284788
    [Abstract] [Full Text] [Related]

  • 18. A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes.
    Nassif ME, Kosiborod M.
    Am J Cardiol; 2019 Dec 15; 124 Suppl 1():S12-S19. PubMed ID: 31741435
    [Abstract] [Full Text] [Related]

  • 19. Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
    Thompson PL, Davis TME.
    Clin Ther; 2017 May 15; 39(5):1012-1025. PubMed ID: 27863704
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.